. Author manuscript; available in PMC: 2016 Jul 15.

Published in final edited form as: Am J Transplant. 2015 Jul;15(7):1817–1826. doi: 10.1111/ajt.13320

Table 2.

Base case results: lifetime costs and health benefits of treatment strategies in cirrhosis and in HCC scenario

Treatment strategy	LYs	Discounted QALYs	Discounted costs (€)	Incremental LYs	Incremental QALYs	Incremental cost (€)	ICER (€/QALY)
HCV-cirrhosis listed for liver transplant
No antiviral treatment	9.76	6.88	€199 998	–	–	–	–
SOF/RBV	13.43	8.96	€292 981	3.67	2.07	€92 983	€ 44 875
HCV-HCC listed for liver transplant
No antiviral treatment	9.76	6.99	€199 998	–	–	–	–
SOF/RBV	13.00	8.83	€311 200	3.23	1.84	€111 202	€60 380

HCC-HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; LYs, life years; QALYs, quality-adjusted life-years; SOF/RBV, treatment with Sofosbuvir and Ribavirin.